Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis
Pilot Study of Efficacy of Topical Nano-liposomal Meglumine Antimoniate (Glucantime) or Paromomycin in Combination With Systemic Glucantime for the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Caused by Leishmania Tropica
Sponsor: Center for Research and Training in Skin Diseases and Leprosy
This EARLY_PHASE1 trial investigates Cutaneous Leishmaniasis and is currently completed. Center for Research and Training in Skin Diseases and Leprosy leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed EARLY_PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed EARLY_PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed Phase 0
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Center for Research and Training in Skin Diseases and Leprosy
- Mashhad University of Medical Sciences
- Tehran University of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .